Screening for Trisomy 21 with Maternal Age, Fetal Nuchal Translucency and Maternal Serum Biochemistry at 11–14 Weeks: A Regional Experience from Germany

Publisher： Karger

E-ISSN： 1421-9964|21|3|264-268

ISSN： 1015-3837

Source： Fetal Diagnosis and Therapy, Vol.21, Iss.3, 2006-04, pp. : 264-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessment of Risk for Chromosomal Abnormalities at 10–14 Weeks of Gestation by Nuchal Translucency and Maternal Age in 5,210 Fetuses at a Single Centre

By  

Fetal Diagnosis and Therapy, Vol. 15, Iss. 3, 2000-04 ,pp. : 170-173

Karger

Access to resources Recommend Favorite

Single-Step Maternal Serum Screening for Trisomy 21 in the Era of Combined or Integrated Screening

By  

Gynecologic and Obstetric Investigation, Vol. 58, Iss. 4, 2004-11 ,pp. : 221-224

Karger

Access to resources Recommend Favorite

Impact of the Maternal Age-Related Risk in First-Trimester Combined Screening for Trisomy 21

By  

Fetal Diagnosis and Therapy, Vol. 30, Iss. 2, 2011-06 ,pp. : 135-140

Karger

Access to resources Recommend Favorite

Maternal Smoking, Obesity and Male Fetal Sex Predispose to a Large Nuchal Translucency Thickness in Healthy Fetuses

By  

Fetal Diagnosis and Therapy, Vol. 29, Iss. 3, 2010-09 ,pp. : 201-207

Karger

Access to resources Recommend Favorite

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

By  

Fetal Diagnosis and Therapy, Vol. 30, Iss. 1, 2011-03 ,pp. : 53-59

Karger

Access to resources Recommend Favorite